Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P69892
UPID:
HBG2_HUMAN
Alternative names:
Gamma-2-globin; Hb F Ggamma; Hemoglobin gamma-2 chain; Hemoglobin gamma-G chain
Alternative UPACC:
P69892; A8MZE0; P02096; P62027; Q14491; Q68NH9; Q96FH6; Q96FH7
Background:
Hemoglobin subunit gamma-2, also known as Gamma-2-globin or Hb F Ggamma, plays a crucial role in fetal development by forming part of fetal hemoglobin F, in combination with alpha chains. This protein is essential for transporting oxygen from the mother to the developing fetus, showcasing its vital function in early human development.
Therapeutic significance:
Transient neonatal cyanosis, a condition marked by reduced oxygen affinity due to abnormal fetal hemoglobin, implicates Hemoglobin subunit gamma-2 in its pathology. Understanding the role of Hemoglobin subunit gamma-2 could open doors to potential therapeutic strategies for managing and possibly preventing this disorder.